mr TODD GILLENWATER

Address concerns with increasing uncertainty and unpredictability of FDA regulatory environment, incl changes to 510(k) process. Address concerns with Medicare Independent Payment Advisory Board (IPAB). Support HR 2182, the Generating Antibiotic Incentives Now (GAIN) Act. Support HR2405, PAHPA Reauthorization.

Address concerns with increasing uncertainty and unpredictability of FDA regulatory environment, incl changes to 510(k) process. Address concerns with Medicare Independent Payment Advisory Board (IPAB). Support HR 2182, the Generating Antibiotic Incentives Now (GAIN) Act.

Address concerns with increasing uncertainty and unpredictability of FDA regulatory environment, incl changes to 510(k) process. Address concerns with Medicare Independent Payment Advisory Board (IPAB). Support HR 2182, the Generating Antibiotic Incentives Now (GAIN) Act. Support HR2405, PAHPA Reauthorization.

Support extension of the R&D tax credit. Support repeal of medical device tax. Support HR 2632, the Life Sciences Jobs and Investment Act.

Support Life Sciences Job & Investment Act (HR 2632). Support repeal of medical device tax. Support extension of Therapeutic Discovery Project program. Support extension of R&D tax credit.

Address provisions in patent reform legislation (HR 1260/S 515) to ensure maintenance of patent enforcement protections and strengthening of patent certainty and value.

Address provisions in patent reform legislation (HR 1260/S 515) to ensure maintenance of patent enforcement protections and strengthening of patent certainty and value; Support efforts to address impact of recent court ruling re patent false markings suit

Address provisions in patent reform legislation (HR 1260/S 515) to ensure maintenance of patent enforcement protections and strengthening of patent certainty and value; Support efforts to address impact of recent court ruling re patent false markings suits

Address provisions in patent reform legislation (HR 1260/S 515) to ensure maintenance of patent enforcement protections and strengthening of patent certainty and value.

Support HR 5116/S 3605, America COMPETES Act Reauthorization. Support education provisions of Labor/HHS/Ed appropriations.

Support HR 5116/S 3605, America COMPETES Act Reauthorization.

Support HR 5116/S 3605, America COMPETES Act Reauthorization. Support education provisions of Labor/HHS/Ed appropriations.

Support HR 5116/S 3605, America COMPETES Act Reauthorization.

Address provisions in patent reform legislation (HR 1260/S 515) to ensure maintenance of patent enforcement protections and strengthening of patent certainty and value; Support efforts to address impact of recent court ruling re patent false markings suits

Address provisions in patent reform legislation (HR 1260/S 515) to ensure maintenance of patent enforcement protections and strengthening of patent certainty and value.

Address provisions in patent reform legislation (HR 1260/S 515) to ensure maintenance of patent enforcement protections and strengthening of patent certainty and value.

Address provisions in patent reform legislation (HR 1260/S 515) to ensure maintenance of patent enforcement protections and strengthening of patent certainty and value; Support efforts to address impact of recent court ruling re patent false markings suit

Support HR 5116, America COMPETES Act Reauthorization. Support education provisions of Labor/HHS/Ed appropriations.

Support HR 5116/S 3605, America COMPETES Act Reauthorization. Support education provisions of Labor/HHS/Ed appropriations.

Support HR 5116/S 3605, America COMPETES Act Reauthorization.

Support HR 5116/S 3605, America COMPETES Act Reauthorization. Support education provisions of Labor/HHS/Ed appropriations.

Support HR 5116/S 3605, America COMPETES Act Reauthorization.

Support HR 5116, America COMPETES Act Reauthorization.

Oppose provisions in patent reform legislation (HR 1260/S 515) that would undermine certainty and weaken patent rights.

Oppose provisions in patent reform legislation (HR 1260/S 515) that would undermine certainty and weaken patent rights.

Oppose provisions in patent reform legislation (HR 1260/S 515) that would undermine certainty and weaken patent rights.

Oppose provisions in patent reform legislation (HR 1260/S 515) that would undermine certainty and weaken patent rights.

Oppose provisions in patent reform legislation (HR 1260/S 515) that would undermine certainty and weaken patent rights.

Support legislation (H.R. 1548) to provide for the approval of follow-on biologics (FOBs) that recognizes the complexity of large molecule product development and manufacturing, emphasizes patient safety, and contains adequate incentives for continued innovation. H.R. 1346/S. 540, Medical Device Safety Act. Oppose removal of medical device preemption provision from existing statute (HR 1346/S 540). Address concerns with application of comparative effectiveness research as a blunt cost containment tool and the consequences to biomedical innovation and patient access.

Support legislation (H.R. 1548) to provide for the approval of follow-on biologics (FOBs) Address concerns with application of comparative effectiveness research as a blunt cost containment tool and the consequences to biomedical innovation and patient access. Oppose removal of medical device preemption provision from existing statute (HR 1346/S 540). Support language in healthcare reform providing incentives for hospitals to prevent and reduce incidence of healthcare-associated infections (HIAs)

Support legislation (H.R. 1548) to provide for the approval of follow-on biologics (FOBs) that recognizes the complexity of large molecule product development and manufacturing, emphasizes patient safety, and contains adequate incentives for continued innovation. H.R. 1346/S. 540, Medical Device Safety Act. Oppose removal of medical device preemption provision from existing statute (HR 1346/S 540). Address concerns with application of comparative effectiveness research as a blunt cost containment tool and the consequences to biomedical innovation and patient access.

Support legislation (HR 1548) to provide for the approval of follow-on biologics (FOBs). Address concerns with application of comparative effectiveness research as a blunt cost containment tool and the consequences to biomedical innovation and patient access. Oppose removal of medical device preemption provision from existing statute (HR 1346/S 540). Support language in healthcare reform providing incentives for hospitals to prevent and reduce incidence of healthcare-associated infections (HIAs). Oppose medical technology manufacturing fee in healthcare reform legislation.

Support legislation (H.R. 1548) to provide for the approval of follow-on biologics (FOBs) that recognizes the complexity of large molecule product development and manufacturing, emphasizes patient safety, and contains adequate incentives for continued innovation. H.R. 1346/S. 540, Medical Device Safety Act. Oppose removal of medical device preemption provision from existing statute (HR 1346/S 540). Address concerns with application of comparative effectiveness research as a blunt cost containment tool and the consequences to biomedical innovation and patient access.

Support legislation (H.R. 1548) to provide for the approval of follow-on biologics (FOBs) Address concerns with application of comparative effectiveness research as a blunt cost containment tool and the consequences to biomedical innovation and patient access. Oppose removal of medical device preemption provision from existing statute (HR 1346/S 540). Support language in healthcare reform providing incentives for hospitals to prevent and reduce incidence of healthcare-associated infections (HIAs)

Support legislation (H.R. 1548) to provide for the approval of follow-on biologics (FOBs) that recognizes the complexity of large molecule product development and manufacturing, emphasizes patient safety, and contains adequate incentives for continued innovation. H.R. 1346/S. 540, Medical Device Safety Act. Oppose removal of medical device preemption provision from existing statute (HR 1346/S 540). Address concerns with application of comparative effectiveness research as a blunt cost containment tool and the consequences to biomedical innovation and patient access.

Support legislation (HR 1548) to provide for the approval of follow-on biologics (FOBs). Address concerns with application of comparative effectiveness research as a blunt cost containment tool and the consequences to biomedical innovation and patient access. Oppose removal of medical device preemption provision from existing statute (HR 1346/S 540). Support language in healthcare reform providing incentives for hospitals to prevent and reduce incidence of healthcare-associated infections (HIAs). Oppose medical technology manufacturing fee in healthcare reform legislation.

Support "Prostate Research, Imaging and Men's Education Act" (S. 756). Support "Viral Hepatitis and Liver Cancer Control and Prevention Act of 2009" (HR 3974).

Support science-based pro-innovation pathway for FDA approval of biosimilars/follow-on biologics in healthcare reform legislation. Address concerns with application of comparative effectiveness research and the consequences to biomedical innovation and patient access. Address concerns with impact of proposed medical device manufacturer fee/tax provision of healthcare reform legislation. Address concerns with proposed independent medicare advisory board entities in healthcare reform legislation. Oppose drug importation provision of healthcare reform legislation. Support "Prostate Research, Imaging and Men's Education Act" (S. 756). Support "Viral Hepatitis and Liver Cancer Control and Prevention Act of 2009" (HR 3974)

Oppose provisions in patent reform legislation (HR 1260/S 515) that would undermine certainty and weaken patent rights.

Oppose provisions in patent reform legislation (HR 1260/S 515) that would undermine certainty and weaken patent rights.

Oppose provisions in patent reform legislation (HR 1260/S 515) that would undermine certainty and weaken patent rights.

Oppose provisions in patent reform legislation (HR 1260/S 515) that would undermine certainty and weaken patent rights.

Oppose provisions in patent reform legislation (HR 1260/S 515) that would undermine certainty and weaken patent rights.

Support legislation (H.R. 1548) to provide for the approval of follow-on biologics (FOBs) Address concerns with application of comparative effectiveness research as a blunt cost containment tool and the consequences to biomedical innovation and patient access. Oppose removal of medical device preemption provision from existing statute (HR 1346/S 540). Support language in healthcare reform providing incentives for hospitals to prevent and reduce incidence of healthcare-associated infections (HIAs)

Support legislation (H.R. 1548) to provide for the approval of follow-on biologics (FOBs) that recognizes the complexity of large molecule product development and manufacturing, emphasizes patient safety, and contains adequate incentives for continued innovation. H.R. 1346/S. 540, Medical Device Safety Act. Oppose removal of medical device preemption provision from existing statute (HR 1346/S 540). Address concerns with application of comparative effectiveness research as a blunt cost containment tool and the consequences to biomedical innovation and patient access.

Support legislation (HR 1548) to provide for the approval of follow-on biologics (FOBs). Address concerns with application of comparative effectiveness research as a blunt cost containment tool and the consequences to biomedical innovation and patient access. Oppose removal of medical device preemption provision from existing statute (HR 1346/S 540). Support language in healthcare reform providing incentives for hospitals to prevent and reduce incidence of healthcare-associated infections (HIAs). Oppose medical technology manufacturing fee in healthcare reform legislation.

Support legislation (H.R. 1548) to provide for the approval of follow-on biologics (FOBs) that recognizes the complexity of large molecule product development and manufacturing, emphasizes patient safety, and contains adequate incentives for continued innovation. H.R. 1346/S. 540, Medical Device Safety Act. Oppose removal of medical device preemption provision from existing statute (HR 1346/S 540). Address concerns with application of comparative effectiveness research as a blunt cost containment tool and the consequences to biomedical innovation and patient access.

Support "Prostate Research, Imaging and Men's Education Act" (S. 756). Support "Viral Hepatitis and Liver Cancer Control and Prevention Act of 2009" (HR 3974).

Support science-based pro-innovation pathway for FDA approval of biosimilars/follow-on biologics in healthcare reform legislation. Address concerns with application of comparative effectiveness research and the consequences to biomedical innovation and patient access. Address concerns with impact of proposed medical device manufacturer fee/tax provision of healthcare reform legislation. Address concerns with proposed independent medicare advisory board entities in healthcare reform legislation. Oppose drug importation provision of healthcare reform legislation. Support "Prostate Research, Imaging and Men's Education Act" (S. 756). Support "Viral Hepatitis and Liver Cancer Control and Prevention Act of 2009" (HR 3974)

Support permanent exemption from Section 404(b) of Sarbanes-Oxley Act for smaller reporting companies (HR 4173).

H.R. 1321, Medicare Advanced Laboratory Diagnostics Act of 2007; H.R. 5765, to amend title XVIII of the Social Security Act to cover remote patient management services for certain chronic health conditions under the Medicare Program; address the consequences of the inappropriate applications of comparative effectiveness research when used simply as a cost containment mechanism.

H.R. 1321, Medicare Advanced Laboratory Diagnostics Act of 2007. H.R. 5765, to amend title XVIII of the Social Security Act to cover remote patient management services for certain chronic health conditions under the Medicare Program; address the consequences of the inappropriate applications of comparative effectiveness research when used simply as a cost containment mechanism.

H.R. 1321, Medicare Advanced Laboratory Diagnostics Act of 2007. H.R. 5765, to amend title XVIII of the Social Security Act to cover remote patient management services for certain chronic health conditions under the Medicare Program; address the consequences of the inappropriate applications of comparative effectiveness research when used simply as a cost containment mechanism.

H.R. 1321, Medicare Advanced Laboratory Diagnostics Act of 2007; support efforts to provide for Medicare coverage of remote patient management services for chronic health care conditions; address the consequences of the inappropriate applications of comparative effectiveness research when used simply as a cost containment mechanism.

H.R. 1908 and S. 1145, Patent Reform Act of 2007, provisions on damages, post-grant review, PTO rule-making, inequitable conduct and mandatory search requirements.

Support legislation (H.R. 5269 and H.R. 1956) to provide for the approval of follow-on biologics (FOBs) that recognizes the complexity of large molecule product development and manufacturing, emphasizes patient safety, and contains adequate incentives for continued innovation. Address concerns with application of comparative effectiveness research as a blunt cost containment tool and the consequences to biomedical innovation and patient access. Oppose removal of medical device preemption provision from existing statute. Support legislation enacting a uniform federal pedigree standard for prescription drugs.

Support legislation (H.R. 5269 and H.R. 1956) to provide for the approval of follow-on biologics (FOBs) that recognizes the complexity of large molecule product development and manufacturing, emphasizes patient safety, and contains adequate incentives for continued innovation. Address concerns with application of comparative effectiveness research as a blunt cost containment tool and the consequences to biomedical innovation and patient access. Oppose removal of medical device preemption provision from existing statute. Support legislation enacting a uniform federal pedigree standard for prescription drugs.

Support legislation (H.R. 5269 and H.R. 1956) to provide for the approval of follow-on biologics (FOBs) that recognizes the complexity of large molecule product development and manufacturing, emphasizes patient safety, and contains adequate incentives for continued innovation. Address concerns with application of comparative effectiveness research as a blunt cost containment tool and the consequences to biomedical innovation and patient access. Oppose removal of medical device preemption provision from existing statute. Support legislation enacting a uniform federal pedigree standard for prescription drugs.

Support legislation (H.R. 5269 and H.R. 1956) to provide for the approval of follow-on biologics (FOBs) that recognizes the complexity of large molecule product development and manufacturing, emphasizes patient safety, and contains adequate incentives for continued innovation. Address concerns with application of comparative effectiveness research as a blunt cost containment tool and the consequences to biomedical innovation and patient access. Oppose removal of medical device preemption provision from existing statute. Support legislation enacting a uniform federal pedigree standard for prescription drugs.

Support legislation (H.R. 5269 and H.R. 1956) to provide for the approval of follow-on biologics (FOBs) that recognizes the complexity of large molecule product development and manufacturing, emphasizes patient safety, and contains adequate incentives for continued innovation. Address concerns with application of comparative effectiveness research as a blunt cost containment tool and the consequences to biomedical innovation and patient access. Oppose removal of medical device preemption provision from existing statute. Support legislation enacting a uniform federal pedigree standard for prescription drugs.

Support legislation (H.R. 5269 and H.R. 1956) to provide for the approval of follow-on biologics (FOBs) that recognizes the complexity of large molecule product development and manufacturing, emphasizes patient safety, and contains adequate incentives for continued innovation. Address concerns with application of comparative effectiveness research as a blunt cost containment tool and the consequences to biomedical innovation and patient access. Oppose removal of medical device preemption provision from existing statute. Support legislation enacting a uniform federal pedigree standard for prescription drugs.

H.R. 1321, Medicare Advanced Laboratory Diagnostics Act of 2007. H.R. 5765, to amend title XVIII of the Social Security Act to cover remote patient management services for certain chronic health conditions under the Medicare Program; address the consequences of the inappropriate applications of comparative effectiveness research when used simply as a cost containment mechanism.

H.R. 1321, Medicare Advanced Laboratory Diagnostics Act of 2007. H.R. 5765, to amend title XVIII of the Social Security Act to cover remote patient management services for certain chronic health conditions under the Medicare Program; address the consequences of the inappropriate applications of comparative effectiveness research when used simply as a cost containment mechanism.

H.R. 1321, Medicare Advanced Laboratory Diagnostics Act of 2007; H.R. 5765, to amend title XVIII of the Social Security Act to cover remote patient management services for certain chronic health conditions under the Medicare Program; address the consequences of the inappropriate applications of comparative effectiveness research when used simply as a cost containment mechanism.

Support efforts to strengthen K-12, undergraduate and post-graduate science, technology, engineering, and math (STEM) education. H.R. 6104, to provide for the coordination of the Nation's science, technology, engineering, and mathematics education initiatives.

Support efforts to strengthen K-12, undergraduate and post-graduate science, technology, engineering, and math (STEM) education. H.R. 6104, to provide for the coordination of the Nation's science, technology, engineering, and mathematics education initiatives.

Support efforts to strengthen K-12, undergraduate and post-graduate science, technology, engineering, and math (STEM) education. H.R. 6104, to provide for the coordination of the Nation's science, technology, engineering, and mathematics education initiatives.

H.R. 1908 and S. 1145, Patent Reform Act of 2007, provisions on damages, post-grant review, PTO rule-making, inequitable conduct and mandatory search requirements.

H.R. 1321, Medicare Advanced Laboratory Diagnostics Act of 2007; support efforts to provide for Medicare coverage of remote patient management services for chronic health care conditions; address the consequences of the inappropriate applications of comparative effectiveness research when used simply as a cost containment mechanism.

H.R. 1908 and S. 1145, Patent Reform Act of 2007, provisions on damages, post-grant review, PTO rule-making, and mandatory search requirements.

H.R. 3161 and S. 1859, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2008, provisions on funding for FDA and NIH and on the importation of prescription drugs; H.R. 2043, Medicaid Access Project through Information Technology (MAP IT) Act; S. 1710, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2008; H.Rept. 110-497.

H.R. 1908 and S. 1145, Patent Reform Act of 2007, provisions on damages, post-grant review, PTO rule-making, and mandatory search requirements.

H.R. 3161 and S. 1859, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2008, provisions on funding for FDA and NIH and on the importation of prescription drugs; H.R. 2043, Medicaid Access Project through Information Technology (MAP IT) Act; S. 1710, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2008; H.Rept. 110-497.

H.R. 3043 and S. 1710, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act 2008, provisions on funding for NIH; H. Rept. 110-497.

H.R. 3161 and S. 1859, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2008, provisions on funding for FDA and NIH and on the importation of prescription drugs; H.R. 2043, Medicaid Access Project through Information Technology (MAP IT) Act; S. 1710, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2008; H.Rept. 110-497.

H.R. 3043 and S. 1710, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act 2008, provisions on funding for NIH; H. Rept. 110-497.

H.R. 3161 and S. 1859, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2008, provisions on funding for FDA and NIH and on the importation of prescription drugs; H.R. 2043, Medicaid Access Project through Information Technology (MAP IT) Act; S. 1710, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2008; H.Rept. 110-497.